Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • LEO Pharma

    - PMLiVE

    LEO Pharma receives NICE approval for chronic hand eczema cream

    The cream can now be prescribed for patients when topical corticosteroids have not worked or are not suitable

    - PMLiVE

    LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema

    The cream is now the first treatment approved by the regulator specifically for this patient population

    - PMLiVE

    LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

    Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

    - PMLiVE

    LEO Pharma and the Parker Institute join forces to advance dermatology research

    The alliance will aim to discover molecules that could be incorporated into wider pharmaceutical research

    - PMLiVE

    LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

    Approximately 125 million people worldwide are affected by some form of the inflammatory condition

    - PMLiVE

    LEO and DEBRA Research partner to advance epidermolysis bullosa treatments

    There is currently no cure for the group of rare inherited skin disorders

    - PMLiVE

    LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab

    The drug was approved by the EC last year to treat nasopharyngeal and oesophageal cancer

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    LEO Pharma’s Anzupgo cream granted MHRA approval to treat chronic hand eczema

    Anzupgo is the first topical pan-JAK inhibitor approved specifically for adults with moderate-to-severe cases

    - PMLiVE

    LEO Pharma shares final long-term results for atopic dermatitis drug Adbry

    The inflammatory skin condition affects over 26 million people in the US alone

    - PMLiVE

    LEO Pharma’s Anzupgo cream approved by EC to treat chronic hand eczema

    About 70% of patients with severe cases of the skin condition report problems performing everyday activities

    - PMLiVE

    LEO Pharma receives CHMP recommendation for Anzupgo in chronic hand eczema

    About 70% of patients with severe cases of the skin condition report problems performing everyday activities

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links